Cannabis Bioscience International Holdings, Inc.

HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation. This achievement is a testament of the paradigm shift which will allow patients and the medical industry to consider cannabinoids as the first option, not a last resource. Our significant valuation is the outcome of our unwavering dedication to growth and our persistent commitment to enhancing standards within the healthcare landscape. With a steadfast focus on maintaining market integrity and propelling scientific evolution, our CEO, Dante Picazo, shares his enthusiasm: "Together, we're paving the way for the future of healthcare, and we're enthusiastic about embarking on this shared adventure of advancement." At CBIH, we embrace a global approach that integrates neuroscience principals, which are revolutionizing modern medicine with clinical, social, and personal implications by understanding the neural-physical relationship, says Dr. Salguero PhD in Science specialized in Microbiology from São Paulo Brazil University. To conclude, our tireless dedication to excellence compels us to fortify our message daily with groundbreaking and premium solutions for those who depend on us for their well-being. Cannabis Bioscience International Holdings stands optimally positioned to advance its market footprint, innovate fresh therapeutic alternatives, and reassert its unwavering commitment to innovation and excellence in the cannabis industry. Moving ahead, we maintain relentless resolve in our pursuit to redefine norms and positively influence the future landscape of cannabis-based wellness. FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com. For more information contact us at: (214) 733-0868 ir@cbih.net Dante Picazo CEO - CBIH Website: www.cbih.net X: www.twitter.com/cbihstock Instagram: www.instagram.com/CBIHSTOCK Investor Relations: East Coast Peter Nicosia Bull in Advantage, LLC Phone: 585-703-6565 Email: Info@BlueHorseshoeStocks.com West Coast Zach Logan Pacific Capital Markets LLC Phone: 858.864.0011 Email: pacificcapitalmarketsllc@gmail.com

Houston, Texas--(News - June 17, 2024) - Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 Billion following a rigorous evaluation by StoneBridge Advisory, a leading financial advisory firm based in Los Angeles, California. StoneBridge's assessment highlights CBIH's formidable market presence, cutting-edge product offerings, and solid business framework. Moreover, this valuation serves as a testament to investor and analyst optimism regarding CBIH's capacity for sustained growth and expansion. The valuation was reached through a comprehensive review of CBIH's financial metrics, market penetration, industry competition, and strategic planning. Additionally, it took into account the exceptional skill sets within the company. Including securities attorney; corporate attorney, patent attorney, in-house counsel, comptroller with a Magister Scientiarum in Administration, CPA, PCAOB, graphic designer, Master's Degree in Audiovisual Communication and Advertising Content, Ph.D.-level scientists with emphasis on microbiology, medical professionals certified in cancer biology, peritoneal dialysis, pregnancy-related emergency care, as well as board-certified in General medicine and internal medicine, Anti-aging medicine Specialist, Master of Health Care Administration, and Doctorate in Dental Surgery. These experts have contributed to the development of a diversified portfolio of innovative therapies and medical solutions over the past 15 years. Their work addresses gaps in conventional treatments, and provides natural alternatives for widespread health issues globally. StoneBridge Advisory employed meticulous due diligence and sophisticated financial modeling during the valuation process to guarantee precision and accurately represent the value of CBIH. John Jones, Treasurer and Director of CBIH, commented on the significance of this valuation, stating: "We have been meticulously reconstructing our company and reinforcing its foundations. Given the promising opportunities we've identified, obtaining a valuation became the next logical step to gauge our progress and plan for future growth." He further noted, "Being positioned in rapidly evolving sectors like medical cannabis, clinical research, and biotechnology, coupled with our unparalleled expertise, positions us uniquely to seize advantageous opportunities that will benefit both our company and shareholders." This landmark $2 Billion valuation positions CBIH among an elite group of startups and fresher/emerging companies that have achieved such a notable feat. This milestone paves the way for CBIH to pursue strategic alliances, investment opportunities, and ambitious expansion strategies, further cementing its status as a leader in the cannabis bioscience sector. FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on . For more information contact us at: (214) 733-0868 ir@cbih.net Dante Picazo CEO - CBIH Website: X: Instagram: Investor Relations: East Coast Peter Nicosia Bull in Advantage, LLC Phone: 585-703-6565 Email: Info@BlueHorseshoeStocks.com West Coast Zach Logan Pacific Capital Markets LLC Phone: 858.864.0011 Email: pacificcapitalmarketsllc@gmail.com To view the source version of this press release, please visit

Houston, Texas--(News - March 20, 2024) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH) has announced the enrollment of the first patient for the clinical trial of its new intra-articular cannabinoid-based injection for knee osteoarthritis. The company plans to test the product on its first participant, and after careful collection and analysis of clinical outcomes, start enrollment of a bigger sample of patients to administer the treatment and further evaluate its efficacy. The innovative and innocuous formulation, Orthocann, is composed of compounds (naturally produced by our organism) and our signature cannabinoids. This formulation could promote the slowing and regression of knee cartilage damage, aiding in lubrication and absorbing shock as the synovial fluid. Hopefully, through our clinical studies, this will represent an alternative to corticosteroid injections which can provide relief but have detrimental effects associated with its repetitive use, including tissue damage and systemic adverse events. Dr. José Torres MD, CBIH National Medical Director and Rosangel Andrades, CBIH Research and Development Director, expressed optimism about this new knee injection, stating that this therapy could significantly improve quality of life for individuals who are eligible for knee replacement surgery or suffering from osteoarthritis and help them regain physical autonomy. "This medication could definitely mark a significant milestone in the field of orthopedic medicine. We have gathered so much research over the years and we are about to transform the science into what could be the perfect antidote," says Dr. Torres. This potential new medication is set to undergo rigorous clinical trials and due to U.S. regulations it is expected to be developed in Colombia, Mexico or Houston, TX depending on cannabis declassification. The clinical study of Orthocann's injection is designed to provide key information that evaluates its safety, tolerability, pharmacokinetics and efficacy. Our efforts intend to build upon our leadership and provide the opportunity to further impact the global burden of knee osteoarthritis, a leading cause of disability in older people, with a worldwide distribution. CBIH believes that this injection could naturally promote cartilage regeneration. Through the emerging mechanism of biotechnology and nanoplatforms applied to Orthocann, it could provide longer effects than current treatments, and become an opportunity for relief of a prevalent and yet difficult-to-treat condition. For more information contact us at: (214) 733-0868 ir@cbih.net Dante Picazo CEO - CBIH Website: X: Instagram: Investor Relations: East Coast Peter Nicosia Bull in Advantage, LLC Phone: 585-703-6565 Email: Info@BlueHorseshoeStocks.com West Coast Zach Logan Pacific Capital Markets LLC 858.864.0011 pacificcapitalmarketsllc@gmail.com To view the source version of this press release, please visit